Advisors
| Michael Bunker Venture Partner Arboretum Ventures |
William R. Clark, MD VP, Med Strategy and Therapy Devel Baxter Healthcare |
Jonathan Conta Group Marketing Manager Intuitive Surgical |
||
| Nick Deeter Founder, Chairman of the Board Orthopediatrics |
Brian Duncan, MD Vice President BioEnterprise |
Todd Englander Director Business Development Cook Medical |
||
| Marc Galletti Managing Director Longitude Capital |
David Gibel Managing Director Children’s Medical Ventures, Philips |
Steve Girouard, Ph.D CEO Securus Medical |
||
| Mike Hess VP, Bradycardia R&D, CRDM Division Medtronic |
William E. King Chief Executive Officer Medical Predictive Science Corporation |
Bob Kroslowitz President and CEO Berlin Heart Inc. |
||
| Ron Lancaster VP of Engineering STDMed |
Kevin Mayberry Director New Technology Endologix |
Read McCarty CEO SunShine Medical LLC |
||
| Dave Mittl Corporate Director B. Braun Interventional Systems |
William M. Moore CEO & President IRIDEX Corporation |
Michael C. Morton Vice President Corporate Regulatory Affairs Medtronic, Inc. |
||
| Prashant Rawat VP, R&D & Quality Mainstay Medical, Inc |
Tom Robinson VP, Strategy and Business Development Boston Scientific |
Aaron Sandoski Co-founder and Managing Director Norwich Ventures |
||
| John Schultz VP, Clinical Acutus Medical |
Tom Thornbury Co-Founder and CEO Neotech Products |
Andrew Yoo, MD Medical Director Ethicon Endo-Surgery |
Venture Partner, Arboretum Ventures
Mike has many areas of expertise but has recently focused a lot of time on the treatment of stroke and on catheter-related technologies, particularly those that reduce the incidence of nosocomial infection. Among Mike’s investments are Juventas Therapeutics, Cardiox, Histosonics, Great Lakes Pharmaceuticals, and CytoPherx. Prior to joining Early Stage Partners as Managing Director in 2008, Mike held roles in sales management and corporate acquisitions for C.R. Bard Access Systems (NYSE: BCR). As Director of Corporate Development, he created the process to evaluate medical technology investments for Bard’s six centralized divisions and successfully executed 14 acquisitions, licenses, and divestitures. Later, Mike managed a field sales force and negotiated multiple contracts with hospitals. Mike joined Medtronic (NYSE: MDT) in 1998 where he initially led a $750 million global product launch in cardiac rhythm management and served on product development, strategy and clinical committees. Mike then served in Medtronic’s corporate development group, closing over ten minority investments and acquisitions in support of corporate strategy initiatives across the neurostimulation, cardiac rhythm management, orthopedic and vascular business units. Mike also served in sales and marketing management roles earlier in his career for Apogee Enterprises and Rand McNally. Mike is a graduate of Miami University (B.S.) where he studied Marketing, and the Kellogg Graduate School of Management at Northwestern University (M.B.A.).
Vice President, Medical Strategy and Therapy Development, Baxter Healthcare
Dr. William Clark received his B.S. and M.S. degrees in chemical engineering from Purdue University and M.D. degree from Indiana University. His post-graduate medical training (internal medicine and nephrology) also occurred at Indiana University. After this training, Dr. Clark was a member of the Renal Division at Baxter for eight years and has been with Gambro’s Acute business unit for the past nine years. He also served as an adjunct member of the Department of Medicine at Indiana University for several years. His current position is Vice President, Medical Strategy and Therapy Development for Gambro. Dr. Clark has worked in the field of dialysis for the past 25 years, both in the AKI and ESRD domains. His clinical areas of research have been CRRT, dialysis kinetics, and membrane transport. On these topics, he has over 100 publications and book chapters, including contributions to the Pediatric Dialysis textbook edited by Warady et al. In addition, he has given over 200 invited presentations on dialysis-related topics at global conferences over the past two decades.
Group Marketing Manager, Intuitive Surgical
Jon is currently the Group Marketing Manager at Intuitive Surgical, the world leader in robotic-assisted surgery. He has guided the largest procedural business at Intuitive Surgical (Gynecology) for the past 3 years, establishing da Vinci Surgery as both the gold standard surgical modality for gynecologic cancers and the #1 minimally invasive treatment for benign hysterectomy. Mr. Conta has previously held positions at C.R. Bard in both Marketing and Corporate Development where he led multiple product launches and white-space assessment of new technologies, as well as assisting in due diligence during the acquisition of a half-dozen private companies. He has authored multiple papers on knee and spine mechanics during his tenure at the Orthopedics Biomechanics Laboratory at Beth Israel Deaconess Medical Center in Boston, and has been involved in the development of novel medical devices for over 15 years. Mr. Conta holds a B.Sc. in Biomechanical Engineering from Brown University and an MBA from the Kellogg School of Management.
Founder, Chairman of the Board, Orthopediatrics
Nick Deeter brings more than 30 years of business leadership and health care industry experience to his past role as OrthoPediatrics’ Chairman of the Board and Managing Director. In these capacities, he leverages his successful record of accomplishment of developing and commercializing medical innovations, orthopedic devices, and implants for the global health care market. Mr. Deeter’s distinguished orthopedic and medical device career began at Zimmer, Inc. and includes more than two decades of executive leadership positions for other well‐respected medical organizations. Prior to forming OrthoPediatrics, he spent seven years with DePuy Orthopaedics, a Johnson & Johnson company where he was responsible for health care compliance administration, medical affairs, and Orthogenesis (custom devices). This included managing surgeon relationships, product engineering, production, and marketing of custom implants and limb preservation products. Mr. Deeter also served as founder, Chairman, President and CEO of ViAtro, Corp., a medical device company specializing in infection control products; Vice President of University Technology Inc. at Case Western Reserve University, managing the technology transfer process of more than $100 million dollars per year of medical research; and President of Medical Ventures Ltd., a venture capital firm that initially funded STERIS Corp. Additionally, he managed the orthopedic and respiratory products at Invacare Corporation, the world leader in durable medical equipment. Mr. Deeter earned an MBA from Case Western Reserve University and a Bachelor of Science degree from Purdue University. He currently serves on the Executive Committee and Board of Trustees of the Corporate Partnership for Economic Growth in Indiana, the Board of Trustees at the Howe Military Academy, Board of Directors at Cardinal Services and RAM Healthcare Group, LLC.
Vice President, BioEnterprise
Brian has been a venture capitalist and was previously a pediatric cardiac surgeon who has more than 20 years of clinical experience. After completing training at Massachusetts General Hospital, he was a staff surgeon at Children’s Hospital in Boston, Seattle Children’s Hospital and Cleveland Clinic. Brian also has experience developing pediatric ventricular assist devices. Most recently, Brian was the Medical Director for Cleveland Clinic Emerging Businesses Unit. He has authored more than 100 peer-reviewed manuscripts, 25 book chapters, and the definitive textbook on pediatric circulatory support entitled Mechanical Support for Cardiac and Respiratory Failure in Pediatric Patients. He serves on the boards of BioOhio, American Society for Artificial Internal Organs and Accord Biomaterials. Brian received his B.S. and M.D. degrees from Indiana University and also has an M.B.A. from the University of Michigan.
Director Business Development, Cook Medical
Todd has spent 30 years in the medical device industry, initially in the fields of sales, and management, and more recently in Business Development for Cook Medical, a forerunner in the development, manufacture, and sales of pediatric medical devices. After attaining a BS in Chemistry, and Biology at Valparaiso University, Todd began his career at Cook working with ICU-based specialties, across a broad spectrum of cardiovascular devices, drainage catheters, difficult airway equipment, and feeding tubes. During that time he was directly involved with the development, and modification of slightly over a dozen products specific to the pediatric market. Todd was one of the initial organizers of the Pediatric Critical Care Colloquium, and has experience in designing multi-institutional catheter trials, including the first to utilize antibiotic-impregnation catheters. His current focus includes working with clinicians, researchers, and academic institutions to organically develop technology for a litany of critical care applications.
Managing Director, Longitude Capital
Marc focuses on investments in medical devices and specialty pharmaceuticals, including drug-device combinations. From 2003 to 2006, Mr. Galletti was a Senior Vice President of Pequot Ventures where he worked in the life sciences practice. Prior to Pequot, Mr. Galletti worked at Amerindo Investment Advisors and Vector Fund Management where prior venture capital investments included Align Technology (NASDAQ: ALGN), CancerVax (acquired by Micromet), Eyetech Pharmaceuticals (NASDAQ: OSIP) and Theravance (NASDAQ: THRX). Mr. Galletti has also worked in the Global Healthcare Investment Banking Group at J.P. Morgan & Co. Mr. Galletti began his life sciences industry career 16 years ago at APM, a management consultancy dedicated to improving operations performance within large acute-care hospitals. He currently serves on the Board of Velomedix and he has been a board member or board observer of Altiva Corporation, Aptus Endosystems, Broncus Technologies, Facet Solutions, MAP Pharmaceuticals (NASDAQ: MAPP), Sadra Medical, Sanarus Medical and Threshold Pharmaceuticals (NASDAQ: THLD). He also sits on the advisory boards for the Center of Biotechnology Management at the Kellogg School of Management and the Program for Biomedical Engineering at Brown University. Mr. Galletti holds an M.B.A. from the Kellogg School of Management at Northwestern University and an A.B. from Princeton University.
CEO, Securus Medical
Steve currently serves as the CEO of Securus Medical. Previously, he was Vice President, Emerging Technologies for the Corporate Office of Science and Technology at Johnson & Johnson. Steve earned an undergraduate degree in Biomedical Engineering from Boston University and his Master’s and Doctoral degrees in Biomedical Engineering from Case Western Reserve University. Steve started his career at Guidant Corporation in the Cardiac Rhythm Management division where he held various technology management positions. As Director of Basic Research at Guidant his responsibilities included the development of breakthrough cardiovascular technologies through a combination of internal and external research and development programs. Steve was recruited to the Cleveland Clinic to serve as the founding Executive Director of the Atrial Fibrillation Innovation Center, a center created for the development of novel technologies for the treatment of atrial fibrillation. Steve was previously a partner with Omega Funds and Oakwood Medical Investors where he focused on cardiovascular opportunities and medical devices. He holds over twenty patents and has authored numerous peer-reviewed articles and book chapters in the fields of cardiology and electrophysiology.
Vice President, Bradycardia R&D, CRDM Division, Medtronic
Mike Hess is the VP of Bradycardia R&D, CRDM Division at Medtronic. Mike has been at Medtronic for 21 years, with experience in R&D, corporate technology, clinical trial management, program management and product planning marketing. Mike is a Medtronic Technical Fellow, a member of the Medtronic Bakken Society, an AIMBE fellow, and has about 25 issued patents and numerous publications. He has a BS in biomedical engineering from Case Western Reserve University and a MS in software engineering from the University of St. Thomas. Most recently Mike was the Vice President of Corporate Technology and Innovation with responsibility for enterprise innovation initiatives and planning for regional R&D activities in the emerging markets.
Chief Executive Officer, Medical Predictive Science Corporation
William King has 14 years of experience with medical device research and development, regulatory approval, and sales and marketing. King was one of the original two employees when Medical Predictive Science Corporation (MPSC) was founded in 2002 with the mission to commercialize neonatal heart rate variability technology developed and licensed from an academic medical center. MPSC is now a profitable company, with over 1000 Neonatal Intensive Care Unit beds monitored by its flagship product, HeRO. King was a co-developer of the HeRO system, a novel monitoring system for infants that is able to detect illnesses and early signs of distress that are commonly caused by infections. King has been directly involved in all aspects of the HeRO system’s development since its inception, including engineering, fundraising, marketing, and all quality and regulatory requirements. King also oversaw MPSC’s sponsorship of the largest randomized clinical trial of a medical device completed in neonatology, which was co-sponsored by the National Institutes of Health (NIH) and MPSC. The study of more than 3,000 preterm infants demonstrated a 20 percent reduction in mortality for those patients whose care included the HeRO system. Prior to joining MPSC, King was as a senior research engineer at Medical Automation Systems in Charlottesville, Va. where King collaborated with researchers from the University of Virginia to develop the technology used in the HeRO system. Prior to MPSC, King worked in industry where he developed his graduate research into three multi-modality commercial machine vision systems. King has been continuously involved in technology transfer since 1995.
President and CEO, Berlin Heart Inc.
Mr. Kroslowitz serves as the President and CEO of Berlin Heart Inc. and is responsible for the company’s business interests in the US, Canada, Mexico, and the countries comprising South America and is currently focused on evaluating new business opportunities for potential funding and/or acquisition. He served as Vice President of Clinical Affairs for the company and was responsible for successfully bringing the first ever viable long term circulatory support option for the pediatric population through the regulatory approval process in the US, Canada, and Mexico. Bob has commercialized five pediatric devices. He commercialized the EXCOR Pediatric Ventricular Assist Device System, the only viable long term circulatory support system available worldwide that was developed specifically for the pediatric population. He also led the effort to commercialize the Jostra HL-20 Heart Lung Machine for use during pediatric open heart surgery, Jostra’s Quadrox oxygenation system for short term pulmonary support, and the Jostra HL-30 temperature control system. He also commercialized the RotaFlow Centrifugal Pump for short term use in ECMO and left, right or biventricular circulatory support in the pediatric population. In addition to the products identified above, Mr. Kroslowitz was involved in the design and development of a novel pediatric cardioplegia system, a pediatric arterial line filtration system, a neonatal oxygenation system, and a neonatal perfusion system that allowed for the elimination of blood in cardiopulmonary bypass system for infants. Also, in addition to contributing to the research and development and commercialization of pediatric devices, Mr. Kroslowitz managed for some time the Pediatric Cardiac Surgery Research Lab at Columbia Presbyterian Medical Center in New York where he oversaw the initial animal work for some of the products listed above. He has also participated on panels related to pediatric device development and commercialization with representatives from the medical community and the governmental regulatory bodies, speaks frequently on topics related to pediatric device development, approval and commercialization, and has served as an advisor to several medical device companies.
VP of Engineering, STDMed
Mr. Lancaster has led global medical device R&D teams for over 24 years and has provided consulting services to entrepreneurs, corporate investors and contract R&D/Manufacturers in medical device and biotech technologies. His experiences include 11 years with Stryker including Division Leader, Stryker Development, 10 years with J&J across three Divisions and consulting with RTI Biologics, Ximedica, Global Guidepoint, and Vice Chairman of CIBOR technologies. His has a BSME with Biomedical Engineering Certification and a MS in Biomechanics from the Michigan State University Colleges of Osteopathic Medicine and Engineering. As Vice President of Stryker Development he focused on the identification, incubation, development and delivery of high potential technologies that resulted in the formation of a new Division, Stryker Orthobiologics and a new obesity LLC. Mr. Lancaster’s product development experiences include technologies in protein formulation, neurostimulation, craniomaxillofacial implants, obesity, biomaterials, surgical navigation, laparoscopic instrumentation, cardiac catheter delivery systems, hydrocephalus, bracing, and sports medicine implants.
Director New Technology, Endologix
Kevin has over 10 years of medical device product development experience in both catheter and implant based technologies. Kevin has lead four products from inception to commercialization helping to improve market share for Endologix. In his most recent position with the company he has relocated to Europe for an assignment to launch two new innovative products and help develop the European organization. In addition to this role he evaluates new technologies for Endologix. Prior to Endologix he worked for Edwards Lifescience’s Heart Valve Division as an Research and Development Engineer with a focus on surgical heart valve replacement and repair.
CEO, SunShine Medical LLC
Read has developed and marketed products for premature babies for more than 20 years. He was the founder and CEO of Hawaii Medical, acquired by Natus, (NASDAQ: BABY), and CEO and founder of Children’s Medical Ventures, acquired by Respironics (NASDAQ: RESP, now Phillips). Read’s basic research includes work at Boston Children’s Hospital in blood separation technologies related to Thalassemia and other blood disorders. Currently, Read travels all over the US to meet with clinicians to discover needs and product improvements for the NICU.
Corporate Director, B. Braun Interventional Systems Inc
Dave has 23 years of Medical Device Sales, Marketing, Business Development, Product Development, and Product Commercialization experience. Dave has spent the last 10+ years of his career responsible for seeking out, developing, and commercializing new technology and product platforms for B. Braun Medical Inc., and their business partners in Business Development and Business Unit Leadership roles. By developing the new product pipeline, both organically and non-organically, Mittl has supported the company’s mission to be the market leading, full line provider of IV therapy solutions and acute pain management, for both acute and non-acute facilities in the US and Canada. In his current role with the B. Braun Medical Interventional Inc., he has a strong portfolio growth focus in the areas of Interventional Radiology and Adult and Pediatric Interventional Cardiology with additional emphasis in the Congenital Heart Defect space.
Chief Executive Officer and President, IRIDEX Corporation
Mr. Moore cofounded of Natus (BABY), a publicly traded company that develops a broad range of medical devices for pediatric use, and has served on its board since1987. Before IRIDEX he served as the Managing Partner of Alpine Partners LLC since May 2008 as well as from 2003 to 2004. From 2004 until May 2008 Mr. Moore was a special limited partner for medical technology at Blue Line Partners, a private equity firm. Mr. Moore currently serves on the board of directors of IRIDEX Corporation (Nasdaq: IRIX) and served on the boards of directors of Criticare Systems, Inc. from 2006 until it was acquired by Opto Circuits (India) Limited in April 2008 and Urologix Inc. (Nasdaq: ULGX) until June 2010. Mr. Moore holds a Bachelor of Science degree in Business from the University of Utah. Mr. Moore brings to the Board more than 25 years of executive experience in the worldwide medical technology field, particularly in the areas of sales, marketing, and product development.
Senior Director, Global Regulatory Affairs, Medtronic, Inc.
Michael is responsible for public health policy and for internal regulatory policy within corporate regulatory affairs. Michael has twenty five years of experience in the medical device industry, including quality, clinical, and regulatory affairs. Before joining Medtronic, Inc., Michael worked with CarboMedics, Inc.; W.L. Gore and Associates; Alcon Labs; and Sorin Group.
Michael has been recognized as a Fellow of the Regulatory Affairs Professional Association (RAPS). He is active in industry groups, including the Advanced Medical Technology Association (AdvaMed). He chairs the AdvaMed PMA Working Group, and is a member of the 510(k) Working Group and the Heart Valve Task Force. Michael is a member of the Pediatric Working Group and is active in efforts to increase access to devices for pediatric and other underserved patient populations. Michael represented industry within Study Group 1 (Premarket) of the Global Harmonization Task Force. He served as the industry representative to the FDA Circulatory System Devices Advisory Panel from 2001 to 2005.
VP, R&D & Quality, Mainstay Medical, Inc
Prashant currently serves as the VP of R&D at a venture-backed company in the field of spine stabilization. Previously he was VP R&D of CSF Therapeutics, a venture-backed Cleveland Clinic spin-off developing a novel invasive therapy for increasing cerebral blood flow in stroke and traumatic brain injury patients. Prior to that he was Technology Fellow & Manager at Boston Scientific CRM (formerly Guidant Corporation) where he managed multiple concurrent technology development & acquisition programs in the Advanced Technology Group. He also served in a technical advisory role & personnel supervision of a multi-discipline engineering team. Prashant earned an M.S.E.E. in Electrical Engineering and Applied Physics from Case Western Reserve University and a B.S.E.E. in Electronics Engineering from Maharaja Sayajirao University
Vice President, Strategy and Business Development, Boston Scientific
Tom Robinson is Vice President, Strategy and Business Development for Boston Scientific’s Urology Division. He is responsible for strategic planning, business development, and portfolio planning for the business. Tom joined Boston Scientific in 2004 to help build and then run the Corporate Strategy group (formerly Marketing Science), which spanned all divisions at Boston Scientific and focused on high-impact projects and improving the state of marketing analytics and decision-making at the company. After 4 years leading strategy, he joined the corporate Business Development team as Vice President, Business Development with corporate responsibilities for the Endoscopy, Urology & Women’s Health, and corporate / white space areas. In 2011, Tom joined the Urology division to focus on growth initiatives. Prior to joining Boston Scientific, he was a Senior Manager at The Boston Consulting Group, where he sold and ran projects for a range of life science and healthcare companies. Tom holds a Bachelor of Arts from the Woodrow Wilson School at Princeton University, a masters in political science from Columbia University, and an MBA from Northwestern University’s Kellogg School of Management.
Co-founder and Managing Director, Norwich Ventures
Aaron is involved in all facets of the investment process and draws from a broad background in healthcare and start-up operations to advise and support companies throughout their growth. Aaron currently serves on the Board of Directors for Daktari Diagnostics, Pelvalon, Podimetrics and Vaxess Technologies. Previously, he served on the board of Intelligent Bio-systems (acquired by Qiagen) and was actively involved in Rhythmia Medical (acquired by Boston Scientific). As the Managing Director, Aaron is responsible for the day-to-day activities of the firm. Prior to co-founding Norwich Ventures, Aaron worked for DEKA, the engineering think tank of Dean Kamen, where he helped develop partnerships and formulate business plans for emerging technologies. Aaron has also worked in start-up operations where he helped launch a subsidiary of Express Scripts and helped launch a venture-backed payments company. Both companies were acquired in transactions totaling over $500 million. Aaron began his career as a consultant at McKinsey & Company, where he advised healthcare clients ranging from leading medical device companies to a rural hospital system. In other healthcare related activities, Aaron serves as a board member of MedTech IGNITE, an initiative of the Massachusetts Medical Device Industry Council (MassMEDIC) for nurturing early-stage medical device entrepreneurs. Aaron earned an MBA from Harvard Business School and graduated summa cum laude from Dartmouth College with a double A.B. in Chemistry and Economics. During graduate school, Aaron was a Teaching Fellow for introductory micro- and macro-economics at Harvard University and was awarded the Allyn Young Teaching Prize at the end of the year. The experience sparked a life-long passion for education and teaching. These days he can be seen guest lecturing on medical technology, innovation, and finance at MIT and Harvard. Aaron is also co-author of How the Wise Decide, a book on decision-making in business (Crown Business, 2008), which has been translated into 11 foreign languages.
VP, Clinical, Acutus Medical
John has 24 years of medical industry experience as an engineer and clinical research professional for in-vitro diagnostics, electrophysiology systems, cardiovascular catheters and implantable products. He is currently the Vice President, Clinical at Acutus Medical working on a new electrophysiology mapping technology. Prior to that he was the Vice President, Clinical Affairs at BridgePoint Medical (now Boston Scientific), which developed devices for crossing chronic total occlusions (CTOs) and Director, Clinical Affairs for Endocardial Solutions (now St. Jude Medical), which developed 3D non-fluoroscopy electrophysiology mapping system. He has also held various clinical positions at EndiCOR Medical (now Covidien), Cordis Webster (now Johnson & Johnson), 3M, and MiniMed Technologies (now Medtronic). John has led several successful IDE studies for a variety devices including CTO catheters, electrophysiology ablation systems, thrombectomy catheters, blood gas monitors, and implantable insulin pumps. He has also been involved in several studies involving pediatric patients, including one that led to the first pediatric indication for cardiac ablation catheters. He has extensive knowledge in clinical trial design with an expertise in clinical interventional cardiology and clinical electrophysiology. John has 2 patents granted and has been an author on several clinical publications.
Co-Founder and CEO, Neotech Products
In the early 1960’s, Tom had a bi-coastal education, with two years at MIT studying Astro Engineering and two years at USC, resulting in a BS in Mechanical Engineering. His first position after college was with Dow Chemical in Michigan where he learned plastics technology – a new field at that time. This specialty lead him into the medical products field where he took a R&D position with American Hospital Supply in CA in 1969. In this role, he developed many medical devices for the IV market and learned the basic technology of the industry. Subsequent positions in the field included R&D, manufacturing, sales and marketing at Cutter Labs (division of Bayer), Spacelabs (division of Squibb) and two startup companies. The broad range of experiences enabled him to start his own medical company. In 1986, with two partners, an M.D. and Bio Engineer, he started Neotech Products, Inc. which specializes in the neonatal and pediatric hospital market. With Tom at the helm as CEO, Neotech has consistently grown over the years to a company of over 100 specialty products, all of which are patented. They are now headquartered in Valencia, CA and have over 30 employees. They sell in all 50 states and more than 50 countries. Their very close relationships with M.D.s, nurses and RTs in the neonatal field have resulted in a wide variety of unique products, many of which were conceived by the clinicians. Over the past two decades, Tom has started four other companies, two of which are in the medical field.
Medical Director, Ethicon Endo-Surgery
Andrew Yoo has a background in engineering and obtained a Masters in Mechanical Engineering from the Georgia Institute of Technology where his research was in computational modeling of human bone. He then attended the University of Texas Southwestern Medical School in Dallas. After obtaining his Medical Doctorate he started his general surgery residency training at the University of Cincinnati. During his residency research years he worked at Ethicon Endo-Surgery (A subsidiary of Johnson and Johnson) as a research fellow. He then transitioned to his current role as a Medical Director at Ethicon Endo-Surgery where he provides medical and scientific expertise for the identification of clinical and healthcare challenges, development and evaluation of technological solutions, medical device safety, and clinical evidence generation for adoption and support worldwide regulatory approval of medical devices.